Ocular Side Effects of EGFR-Inhibitor ABT-414 in Recurrent Glioblastoma: A Long-Term Safety Study

Ocular Side Effects of EGFR-Inhibitor ABT-414 in Recurrent Glioblastoma: A Long-Term Safety Study

This study aimed to prospectively evaluate, on a long-term basis, corneal side effects secondary to compassionate administration of epidermal growth factor receptor (EGFR) inhibitor depatuxizumab mafodotin (ABT-414) in patients affected by EGFR-amplified recurrent glioblastoma. Fifteen patients with...

Full description

Bibliographic Details
Main Authors: Raffaele Parrozzani, Giuseppe Lombardi, Edoardo Midena, Davide Londei, Marta Padovan, Giulia Marchione, Mario Caccese, Giulia Midena, Vittorina Zagonel, Luisa Frizziero
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Oncology
Subjects:
ABT-414
confocal microscopy
cornea
epidermal growth factor receptor-inhibitor
glioblastoma
side effects
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.593461/full

Similar Items

Similar Items